Completed PHASE2 INTERVENTIONAL 2-arm NCT00140244

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients

Sponsor: Amgen

Conditions HAART-induced Lipodystrophy and Metabolic Syndrome

Interventions Placebo r-metHuLeptin

Updated 8 times since 2017 Last updated: Apr 6, 2017 Started: Dec 31, 2001 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HAART-induced Lipodystrophy and Metabolic Syndrome and is currently completed. Amgen leads this study, which shows 8 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2017 — May 2017 [monthly]

Unknown Status PHASE2

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Beth Israel Deaconess Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: Beth Israel Deaconess Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States